China’s State Administration for Market Regulation has postponed its approval of the proposed deal between Synopsys (SNPS) and Ansys (ANSS), The Financial Times’ Zijing Wu and Cheng Leng report. According to two people with knowledge of the matter, the $35B merger has received approval of authorities in the U.S. and Europe, and had entered the last stage of SAMR’s approval process and was expected to be completed by the end of this month. The delay comes as the U.S. moved to ban chip design software sales by U.S. companies, including Synopsys, to China in late May.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNPS:
- M&A News: Synopsys Stock (SNPS) Slumps as Chinese Put Freeze on $35B Ansys Merger
- Synopsys price target lowered to $540 from $575 at KeyBanc
- Synopsys price target lowered to $540 from $590 at Morgan Stanley
- Synopsys Pauses China Sales Amid New Chip Design Export Controls
- Synopsys Reports Strong Q2 Amidst China Challenges